Beam Therapeutics Inc.

Stocks

BEAM

US07373V1052

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			5-day change	1st Jan Change
32.68 ^USD	-8.77%		-6.06%	+17.89%

07-08	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise	MT
07-08	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration	MT

Transcript : Beam Therapeutics Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-20-2026 10

Published on 05/25/2026 at 06:07 pm BST - Modified on 05/25/2026 at 06:41 pm BST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Luca Issi (Analysts)

Capital Market. Today is a great privilege to have Beam as part of our 2026 Global Healthcare Conference. Representing the company, we have John Evans, Chief

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Beam Therapeutics Inc.

07-08	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise	MT
07-08	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration	MT
06-29	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 2000 Value Benchmark	CI
06-28	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 3000E Value Benchmark	CI
06-28	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 3000 Value Benchmark	CI
06-28	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell Small Cap Comp Value Benchmark	CI
06-28	Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell 2500 Value Benchmark	CI
06-18	Beam Therapeutics Receives FDA Clearance for Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria	CI
06-18	Beam Therapeutics Says FDA Clears Investigational New Drug Application for PKU Treatment	MT
05-25	Beam Therapeutics Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-20-2026 10:30 AM
05-18	Beam Therapeutics Inc. Presents Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference	CI
05-07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q1 Revenue $31.7M, vs. FactSet Est of $11.0M	MT
04-02	Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing	MT
04-01	Beam Therapeutics Publishes Beacon Phase 1/2 Data for Risto-Cel in Patients with Sickle Cell Disease	CI